Mark V. Pauly, For The Inquirer

7073彩票登录Professor of Health Care Management, Business Economics and Public Policy at The Wharton School

Latest Stories

The government should pay Americans to take coronavirus tests. Here’s why. l Opinion

People who test positive could be compensated with a lump sum payment to fill the gap in protection against unexpected loss of wages. Plus this policy would strongly motivate people to seek testing, helping contain the virus.

Fed up with outrageous 'surprise’ medical bills? Blame your boss. | Opinion

A key source of confusion is who has allowed this to happen? The answer: physicians, hospital systems, and private insurers who were “basically fine” with the arrangement and were unwilling to make the big concessions needed for change.

Your health insurance is making you ignore your doctor l Opinion

Out-of-pocket spending can make you decide a drug isn't worth taking, despite medical orders.

Medicare for All could bring higher wages, but not for everyone | Opinion

Economists believe that when the premium goes away, at the same salary workers become are a bargain and employers will want to hire more of them. Employers who compete to hire workers will bid up wages until they rise by the amount of the bargain — the original cost of the employer contribution.

Medicare for All and the silly season for health reform l Opinion

So what would be the social benefits and costs of wiping out current patterns of job based insurance coverage and money wages and moving to a new one?

Drug pricing reform in the U.S.: If Europeans paid more, would Americans pay less? | Opinion

The Trump administration seeks to lower US drug prices by focusing on other developed countries (think France) who, in the President’s opinion, are freeloading on American taxpayers and consumers.

Is pharma getting greedier?

There has been considerable consumer and policymaker concern about the rising prices of some prescription drugs, from the thousands-percent increases in the price of generics like Turing Pharmaceuticals' Daraprim to the average 8.8% increase by Pfizer for a large sample of its brand name drugs. Putting aside appeals by brand name firms for the need for funding for research and development (which does not apply to generics), the most attractive explanation for why brand nme drug makers can increase prices is because they can.

Why Medicaid work requirements could help persuade more states to expand coverage

Millions of adult Americans who are under 65, not disabled, and have incomes near the poverty line do not have access to health insurance. Nevertheless, 19 states (Pennsylvania excluded, but Maine so far included) have not yet decided to participate in Obamacare's Medicaid expansion, despite the incentive of large federal matching payments. Those who remain uninsured in these states make up much of the remaining 10 - 15% of the population without coverage. Consequences of being uninsured, like financial distress and lower rates of use of medical care, have been documented for them. What, many of us in states that have implemented the expansion ask, is holding up the parade?

A bipartisan push for more evidence-based public policy - but would it really improve decisions?

The bulk of the report makes noncontroversial recommendations about ways to increase the amount of and access to data on government programs, arguing for more of both.